1 |
Karar J, Maity A (2011). PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci, 4, 51.
|
2 |
Kim HP, Yoon YK, Kim JW, et al (2009). Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PloS One, 4, e5933
DOI
ScienceOn
|
3 |
Kobayashi S, Boggon TJ, Dayaram T, et al (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 352, 786-92.
DOI
ScienceOn
|
4 |
Dittmann K, Mayer C, Fehrenbacher B, et al (2005). Radiation-induced epidermal growth factor receptor nuclear import is linked toactivation of DNA-dependent protein kinase. J Biol Chem, 280, 31182-9.
DOI
ScienceOn
|
5 |
Dittmann K, Mayer C, Rodemann HP (2005). Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol, 76, 157-61.
DOI
ScienceOn
|
6 |
Dittmann K, Mayer C, Rodemann HP (2010). Nuclear EGFR as novel therapeutic target: insights into nuclear translocation andfunction. Strahlenther Onkol, 186, 1-6.
|
7 |
Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T (2006). PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol, 1, 629-34.
DOI
|
8 |
Engelman JA, Zejnullahu K, Mitsudomi T, et al (2007). MET amplification leads to gefitinib resistance in lung cancer by activatingERBB3 signaling. Science, 316, 1039-43.
DOI
ScienceOn
|
9 |
Ettinger DS (2006). Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist, 11, 358-73.
DOI
ScienceOn
|
10 |
Franovic A, Gunaratnam L, Smith K, et al (2007). Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutationalexplanation for its overexpression in human cancer. Proc Natl Acad Sci U S A, 104, 13092-7.
DOI
ScienceOn
|
11 |
Garcia-Cao I, Song MS, Hobbs RM, et al (2012). Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell, 149, 49-62.
DOI
ScienceOn
|
12 |
Gupta AK, Bakanauskas VJ, Cerniglia GJ, et al (2001). The Ras radiation resistance pathway. Cancer Res, 61,4278-82.
|
13 |
Han W, Lo HW (2012). Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor sub-cellular locations. Cancer Lett, 318, 124-34.
DOI
ScienceOn
|
14 |
Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354, 567-78.
DOI
ScienceOn
|
15 |
Bouali S, Chretien AS, Ramacci C, et al (2009). P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Ther, 16, 498-507.
DOI
ScienceOn
|
16 |
Burger JA, Kipps TJ (2006). CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 107, 1761-7.
DOI
ScienceOn
|
17 |
Cao Y, Langer R (2008). A review of Judah Folkman’s remarkable achievements in biomedicine. Proc Natl Acad Sci U S A, 105, 13203-5.
DOI
ScienceOn
|
18 |
Castellino RC, Durden DL (2007). Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point forthe control of angiogenesis in brain tumors. Nat Clin Pract Neurol, 3, 682-93.
|
19 |
Cerniglia GJ, Pore N, Tsai JH, et al (2009). Epidermal growth factor receptor inhibition modulates the microenvironment byvascular normalization to improve chemotherapy and radiotherapy efficacy. PloS One, 4, e6539.
DOI
ScienceOn
|
20 |
Chen DJ, Nirodi CS (2007). The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res, 13, 6555-60.
DOI
ScienceOn
|
21 |
Christofk HR, Vander HMG, Harris MH, et al (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism andtumour growth. Nature, 452, 230-3.
DOI
ScienceOn
|
22 |
Chung TD, Broaddus WC (2005). Molecular targeting in radiotherapy: epidermal growth factor receptor. Mol Interv, 5, 15-9.
DOI
ScienceOn
|
23 |
Das AK, Sato M, Story MD, et al (2006). Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res, 66, 9601-8.
DOI
ScienceOn
|
24 |
Das AK, Chen BP, Story MD, et al (2007). Somatic mutations in the tyrosine kinase domain of epidermal growth factorreceptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lungcarcinoma. Cancer Res, 67, 5267-74.
DOI
ScienceOn
|
25 |
Debucquoy A, Machiels JP, McBride WH, Haustermans K (2010). Integration of epidermal growth factor receptor inhibitors with preoperativechemoradiation. Clin Cancer Res, 16, 2709-14.
DOI
|
26 |
Abdollahi A, Hlatky L, Huber PE (2005). Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat, 8, 59-74.
DOI
ScienceOn
|
27 |
An SJ, Chen ZH, Su J, et al (2012). Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status. PloS One, 7, e40109.
DOI
|
28 |
Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlyingresponsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.
DOI
ScienceOn
|
29 |
Maity A, Pore N, Lee J, et al (2000). Epidermal growth factor receptor transcriptionally up-regulates vascularendothelial growth factor expression in human glioblastoma cells via a pathwayinvolving phosphatidylinositol 3’-kinase and distinct from that induced byhypoxia. Cancer Res, 60, 5879-86.
|
30 |
Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8.
DOI
ScienceOn
|
31 |
Mak RH, Doran E, Muzikansky A, et al (2011). Outcomes after combined modality therapy for EGFR-mutant and wild-type locallyadvanced NSCLC. Oncologist, 16, 886-95.
DOI
ScienceOn
|
32 |
McKenna WG, Muschel RJ (2003). Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer, 38, 330-8.
DOI
ScienceOn
|
33 |
Meert AP, Martin B, Delmotte P, et al (2002). The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J, 20, 975-81.
DOI
ScienceOn
|
34 |
Meyn RE, Munshi A, Haymach JV, et al (2009). Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol, 92, 316-22.
DOI
ScienceOn
|
35 |
Milosevic M, Fyles A, Hedley D, et al (2004). The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol, 14, 249-58.
DOI
ScienceOn
|
36 |
Minjgee M, Toulany M, Kehlbach R, et al (2011). K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys, 81, 1506-14.
DOI
ScienceOn
|
37 |
Mitsudomi T, Morita S, Yatabe Y, et al (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol, 11, 121-8.
DOI
ScienceOn
|
38 |
Mukherjee B, McEllin B, Camacho CV, et al (2009). EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res, 69, 4252-9.
DOI
ScienceOn
|
39 |
Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.
DOI
ScienceOn
|
40 |
Morgan S, Grandis JR (2009). ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res, 315, 572-82.
DOI
ScienceOn
|
41 |
Nicholson RI, Gee JM, Harper ME (2001). EGFR and cancer prognosis. Eur J Cancer, 37, S9-15.
|
42 |
O’Byrne KJ, Danson S, Dunlop D, et al (2007). Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol, 25, 3266-73.
DOI
ScienceOn
|
43 |
Okamoto I, Kenyon LC, Emlet DR, et al (2003). Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci, 94, 50-6.
DOI
ScienceOn
|
44 |
Pao W, Wang TY, Riely GJ, et al (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2, e17.
DOI
ScienceOn
|
45 |
Peng XH, Karna P, Cao Z, et al (2006). Cross-talk between epidermal growth factor receptor and hypoxia-induciblefactor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem, 281, 25903-14.
DOI
ScienceOn
|
46 |
Pollard JW (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 4, 71-8.
DOI
ScienceOn
|
47 |
Pore N, Jiang Z, Gupta A, et al (2006). EGFR tyrosine kinase inhibitors decrease VEGF expression by bothhypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res, 66, 3197-204.
DOI
ScienceOn
|
48 |
Schuurbiers OC, Kaanders JH, der Heijden HF v, et al (2009). The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol, 4, 761-7.
DOI
ScienceOn
|
49 |
Rodemann HP, Dittmann K, Toulany M (2007). Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol, 83, 781-91
DOI
ScienceOn
|
50 |
Sasaki H, Kawano O, Endo K, et al (2007). EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep, 17, 319-23.
|
51 |
Semenza GL (2012). Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci, 33, 207-14.
DOI
ScienceOn
|
52 |
Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3, 721-32.
DOI
ScienceOn
|
53 |
Sherwood LM, Parris EE, Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6.
DOI
ScienceOn
|
54 |
Shigematsu H, Lin L, Takahashi T, et al (2005). Clinical and biological features associated with epidermal growth factor receptorgene mutations in lung cancers. J Natl Cancer Inst, 97, 339-46.
DOI
ScienceOn
|
55 |
Sok JC, Coppelli FM, Thomas SM, et al (2006). Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res, 12, 5064-73
DOI
ScienceOn
|
56 |
Solomon B, Hagekyriakou J, Trivett MK, et al (2003). EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cellcarcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys, 55, 713-23.
DOI
ScienceOn
|
57 |
Sos ML, Koker M, Weir BA, et al (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res, 69, 3256-61.
DOI
ScienceOn
|
58 |
Tomioka A, Tanaka M, De Velasco MA, et al (2008). Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cellsto irradiation. Mol Cancer Ther, 7, 1864-70
DOI
ScienceOn
|
59 |
Stambolic V, MacPherson D, Sas D, et al (2001). Regulation of PTEN transcription by p53. Mol Cell, 8, 317-25.
DOI
ScienceOn
|
60 |
Tang Y, Eng C (2006). PTEN autoregulates its expression by stabilization of p53 in aphosphatase-independent manner. Cancer Res, 66, 736-42.
DOI
ScienceOn
|
61 |
Toulany M, Baumann M, Rodemann HP (2003). Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFRdepends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res, 5, 863-72.
|
62 |
Toulany M, Dittmann K, Kruger M, et al (2005). Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol, 76, 143-50.
DOI
ScienceOn
|
63 |
Wang J, Ouyang W, Li J, et al (2005). Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaBinduced by UV radiation. Cancer Res, 65, 6601-11.
DOI
ScienceOn
|
64 |
Wang X, Schneider A (2010). HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis, 31, 1202-10.
DOI
ScienceOn
|
65 |
Wang Y, Yamaguchi H, Hsu J. et al (2010). Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene, 29, 3997-4006.
DOI
ScienceOn
|
66 |
Weihua Z, Tsan R, Huang WC, et al (2008). Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell, 13, 385-93.
DOI
ScienceOn
|
67 |
Yang W, Xia Y, Ji H, et al (2011). Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature, 480, 118-22.
|
68 |
Xia W, Wei Y, Du Y, et al (2009). Nuclear expression of epidermal growth factor receptor is a novel prognosticvalue in patients with ovarian cancer. Mol Carcinog, 48, 610-7.
DOI
ScienceOn
|
69 |
Yamamoto C, Basaki Y, Kawahara A, et al (2010). Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res, 70, 8715-25.
DOI
ScienceOn
|
70 |
Yamazaki T, Zaal K, Hailey D, et al (2002). Role of Grb2 in EGF-stimulated EGFR internalization. J Cell Sci, 115, 1791-802.
|
71 |
Yu J, Zhang SS, Saito K, et al (2009). PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J, 28, 21-33.
DOI
ScienceOn
|
72 |
Yun CH, Boggon TJ, Li Y, et al (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 11, 217-27.
DOI
ScienceOn
|
73 |
Zander T, Scheffler M, Nogova L, et al (2011). Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F] fluorodeoxyglucose and [(18)F]fluorothymidinepositron emission tomography. J Clin Oncol, 29, 1701-8.
DOI
ScienceOn
|
74 |
Zhang L, Ge W, Hu K, et al (2012). Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol Biol Rep, 39, 89-95.
DOI
|
75 |
Zhong H, Chiles K, Feldser D, et al (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res, 60, 1541-5.
|
76 |
Lammering G, Hewit TH, Valerie K, et al (2003). EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene, 22, 5545-53.
DOI
ScienceOn
|
77 |
Zhong L, Roybal J, Chaerkady R, et al (2008). Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res, 68, 7237-45.
DOI
ScienceOn
|
78 |
Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): amulticentre, open-label, randomised, phase 3 study. Lancet Oncol, 12, 735-42.
DOI
ScienceOn
|
79 |
Koh PK, Faivre-Finn C, Blackhall FH, De Ruysscher D (2012). Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev, 38, 626-40
DOI
ScienceOn
|
80 |
Kokubo Y, Gemma A, Noro R, et al (2005). Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer, 92, 1711-9.
DOI
ScienceOn
|
81 |
Lammering G, Hewit TH, Holmes M, et al (2004). Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radio sensitivity. Clin Cancer Res, 10, 6732-43
DOI
ScienceOn
|
82 |
Lammering G, Valerie K, Lin PS, et al (2004). Radiation-induced activation of a common variant of EGFR confers enhanced radio resistance. Radiother Oncol, 72, 267-73.
DOI
ScienceOn
|
83 |
Li C, Iida M, Dunn EF, et al (2010). Dasatinib blocks cetuximab-and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol, 97, 330-7.
DOI
ScienceOn
|
84 |
Li C, Iida M, Dunn EF, et al (2009). Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene, 28, 3801-13
DOI
ScienceOn
|
85 |
Li J, Yen C, Liaw D, et al (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275, 1943-7.
DOI
ScienceOn
|
86 |
Liang K, Ang KK, Milas L, et al (2003). The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys, 57, 246-54.
DOI
ScienceOn
|
87 |
Lo HW (2010). Nuclear mode of the EGFR signaling network: biology, prognostic value, andtherapeutic implications. Discov Med, 10, 44-51.
|
88 |
Liao HJ, Carpenter G (2009). Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res, 69, 6179-83.
DOI
ScienceOn
|
89 |
Liccardi G, Hartley JA, Hochhauser D (2011). EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res, 71, 1103-14
DOI
|
90 |
Liotta LA, Kohn EC (2001). The microenvironment of the tumour-host interface. Nature, 411, 375-9.
DOI
ScienceOn
|
91 |
Lo HW, Hung MC (2006). Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycleprogression, nitric oxide pathway and patient survival. Br J Cancer, 94, 184-8
DOI
ScienceOn
|
92 |
Lo HW, Xia W, Wei Y, et al (2005). Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res, 65, 338-48.
|
93 |
Lynch TJ, Fenton D, Hirsh V, et al (2009). A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol, 4, 1002-9
DOI
ScienceOn
|
94 |
Hirata A, Ogawa S, Kometani T, et al (2002). ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermalgrowth factor receptor tyrosine kinase. Cancer Res, 62, 2554-60.
|
95 |
Hirata A, Uehara H, Izumi K, et al (2004). Direct inhibition of EGF receptor activation in vascular endothelial cells bygefitinib ('Iressa', ZD1839). Cancer Sci, 95, 614-8.
DOI
|
96 |
Hoshino M, Fukui H, Ono Y, et al (2007). Nuclear expression of phosphorylated EGFR is associated with poor prognosis ofpatients with esophageal squamous cell carcinoma. Pathobiology, 74, 15-21.
DOI
ScienceOn
|
97 |
Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
DOI
ScienceOn
|
98 |
Huang SM, Harari PM (2000). Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res, 6, 2166-74.
|
99 |
Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62.
DOI
ScienceOn
|
100 |
Janmaat ML, Giaccone G (2003). The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc), 39, 61-80.
DOI
ScienceOn
|
101 |
Ji H, Zhao X, Yuza Y, et al (2006). Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A, 103, 7817-22.
DOI
ScienceOn
|
102 |
Jiang BH, Jiang G, Zheng JZ, et al (2001). Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-induciblefactor 1. Cell Growth Differ, 12, 363-9.
|
103 |
Jiang XD, Dai P, Wu J, et al (2012). Effect of recombinant human endostatin on radiosensitivity in patients withnon-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 83, 1272-7
DOI
ScienceOn
|
104 |
Jiang XD, Dai P, Wu J, et al (2011). Inhibitory effect of radiotherapy combined with weekly recombinant human endostatin on the human pulmonary adenocarcinoma A549 xenografts in nude mice. Lung Cancer, 72, 165-71
DOI
ScienceOn
|
105 |
Jung IL, Kang HJ, Kim KC, Kim IG (2010). PTEN/pAkt/p53 signaling pathway correlates with the radioresponse of non-smallcell lung cancer. Int J Mol Med, 25, 517-23.
|
106 |
Karamouzis MV, Grandis JR, Argiris A (2007). Therapies directed against epidermal growth factor receptor in aerodigestivecarcinomas. JAMA, 298, 70-82.
DOI
ScienceOn
|